Vericel Corp

Vericel Corp

  • Price (EUR)30.60
  • Today's Change-1.80 / -5.56%
  • Shares traded0.00
  • 1 Year change+22.55%
  • Beta--
Data delayed at least 15 minutes, as of May 26 2023 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vericel Corporation is engaged in advanced therapies for the sports medicine and severe burn care markets. The Company markets two cell therapy products and one specialty biologic product in the United States. MACI (autologous cultured chondrocytes onporcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single ormultiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.

  • Revenue in USD (TTM)169.31m
  • Net income in USD-17.11m
  • Incorporated1989
  • Employees305.00
  • Location
    Vericel Corp64 Sidney StCAMBRIDGE 02139-4170United StatesUSA
  • Phone+1 (734) 930-5555
  • Fax+1 (734) 665-0485
  • Websitehttps://vcel.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.